



Advancements In Neuroimaging For Alzheimer's Disease Diagnosis: Current Technologies And Future Directions

¹Gadage Ashish Rambhau, ²Dighe Nikita Gorakshnath, ³Dushing Pratibha Sanjay, ⁴Dighe Santosh B

¹Student, ² Student, ³ Student , ⁴Assistent Professor

¹Pharmacology,

¹ Pravara Rural College of Pharmacy, Pravaranagar, Rahata, India

Abstract: This Alzheimer Disease is a modern disease that destroys memory and other essential mental features, In brain the neuron cell connections are destroyed and the cells themselves degenerate and die, eventually destroying memory and different critical intellectual features. Alzheimer's disease is presently ranked on the sixth leading reason of dying inside the US, recent studies imply that the Alzheimer's ailment might also rank 1/3, simply behind heart sickness and most cancers, as a purpose of dying in older people. Some treatments can assist to manipulate the signs and symptoms in a few people, presently there may be no precise treatment is available for this disease.

Here we discuss:

- Reasons of Alzheimer disease
- Non-pharmacological methods for the treatment of Alzheimer ailment
- Different exams (Test)used for early detection of Alzheimer r's ailment.
- Tablets used for brief improvement and symptomatic treatment of Alzheimer disease.
- Earlier stage treatment trials.

The field of Alzheimer Disease studies is advanced in which it is not necessary to justify the importance of prevention as the principle healing goal. After a few many years of studies aimed at advert prevention, there is an abundance of studies in assist of a number of proposed risk and defensive elements. the existing assessment was written in reaction to the evolving remedy techniques and preventive measures of advert.

In this assessment, the foremost effect of diagnostic reliability on the opportunity of figuring out preventive techniques had been discussed. we will additionally assessment the scientific evidence to assist shifting from statement to movement, and the ongoing intervention studies associated with Alzheimer's disorder. we will recognition on methodological troubles, as well as future guidelines to higher balance the person based strategies with population wide strategies of preventions.

Index Terms - Alzheimer's , neurons , Plaques , Detection , sicknesses , implementation

I. Introduction

Alzheimer's sickness is an irreversible and modern brain sickness that slowly destroys reminiscence and thinking abilities and sooner or later, the capability of deliver out the simple tasks.¹ In the majority with the Alzheimer's ailment people with the overdue onset type symptoms first appear of their age of mid-60s. Early onset Alzheimer's occurs between the age of character's 30s and mid-60s and it is very rare. advert is the maximum not unusual reason of dementia a few of the older adults.²

The Alzheimer Disease is called after Dr. Alois Alzheimer. In 12 Disember 1906, Dr. Alzheimer noticed adjustments within the brain tissues of a lady who had died of an unusual intellectual contamination.

Alzheimer Disease is a modern disease that destroys memory and other essential mental features, In brain the neuron cell connections are destroyed and the cells themselves degenerate and die, eventually destroying memory and different critical intellectual features.

Nearly more than five million people are residing with Alzheimer's. by using 2050, this range is projected to boom to almost 14 million.

In United country Alzheimer's ailment is the 6th main cause of demise. between the years from 2000 to 2018, deaths from coronary heart sickness have decreased 7.8% while deaths from Alzheimer's have improved 146%. The number of peoples dwelling with Alzheimer's is developing and growing speedy. greater than 5 million individuals of all age organizations have Alzheimer's. In 2023 an envisioned six million individuals age 65 and older are living with Alzheimer's. 80 percentage sufferers are age 75 or older. 1 in 10 human beings age sixty five and older has Alzheimer's dementia it is approximately 10%. as the number of older human being's grows hastily, so the wide variety of latest and existing cases of Alzheimer's. by way of 2050, the variety of human beings of age 65 and older with Alzheimer's dementia may additionally grow to a projected 13.eight million, barring the development of medical breakthroughs to save you, sluggish or remedy Alzheimer's disease. Despite the fact that deaths from other illnesses have reduced considerably, legitimate information indicate that deaths from Alzheimer's sickness have elevated extensively.

From 2000 to 2018, the number of deaths from Alzheimer's ailment as recorded on dying certificate has greater than doubled, growing 146 %, whilst the wide variety of deaths from the primary purpose of demise coronary heart ailment reduced 7.8 %. amongst humans age 70, sixty one % of these with Alzheimer's are expected to die before the age of 80 as compared with 30 % of people without Alzheimer's a rate two times as high. Peoples of age sixty five and older survive an average of four to 8 years after a analysis of Alzheimer's dementia, but a few human beings live so long as 20 years with Alzheimer's .

Causes Of Alzheimer Disorder:-

- 1) Most of the research display that Alzheimer's ailment is because of genetic, lifestyle and environmental factors that have an effect on the brain.
- 2) The precise reasons of Alzheimer's disease is not understood, however studies proved that in Alzheimer's sickness there may be problems with brain proteins that fail to function generally, those proteins disrupt the work of neuron cells of brain and unharness a sequence of toxic activities, Neurons are damaged, lose connections to each other and in the end die.
- 3) The manner of adverse the place of brain that controls reminiscence is begins years before the first signs and symptoms to appear.
- 4) The lack of neurons spreads to other regions of the brains with the aid of the overdue level of the disorder, the mind has reduced in size extensively.
- 5) Researcher thinks that proteins pay good sized role in Alzheimer's disorder.




Diagram 1-Alzhimers cell in brain

They centered particularly at the role of proteins:

(I) Plaques & (II) Tangles. This displays the sluggish, unsure progression of the Alzheimer's ailment.

I) Plaques :

Within the cellular membrane of the neuron in the mind there is molecule referred to as amyloid precursor protein or APP which enables the neuron to develop and repair itself after an damage. This protein is get used, it get broken down and recycled. Typically, it receives chopped by enzyme alpha-secretase and gamma-secretase, this chopped peptide is soluble. however if protein get chopped via beta-secretase and gamma-secretase than protein isn't soluble and create a monomers known as amyloid beta. Amyloid beta monomers are sticky and that they bond collectively simply outdoor the neurons and shape beta-amyloid plaques. these plaques can get between neurons, which get inside the manner of neuron to neuron signalling due to this mind functions like memory is severely impaired. Theses plaques cause inflammation and damage surrounding neurons.

II) Tangles :

Much like other cells, neurons are held collectively through their cytoskeleton which is partly made from microtubules. A special proteins called tau makes sturdy bonding with microtubules that do not spoil apart them. The beta-amyloid plaques building up outside the neuron initiates pathway in the neuron that ends in activation of kinase. Kinase enzyme transfers phosphate businesses to tau protein. Tau protein then modifications form, stops helping microtubules and clips up with different tau protein and get tangled that is neurofibrillary tangles. Neurons with tangles and nonfunctioning microtubules cannot signal as well, and now and again emerge as present process apoptosis, or programmed cell dying. As neurons die, massive scale adjustments begins to takes area inside the mind.

Early Detection And Check Of Alzheimer Illnesses:-

In 12 months 1906, Dr. Alzheimer noticed adjustments in the brain tissue of a lady who had died of an unusual mental contamination. Her signs covered reminiscence loss, language troubles, and unpredictable conduct. After she died, he tested her mind and located many odd clumps called amyloid plaques and tangled bundles of fibers recognise as neurofibrillary, or tau, tangles.

These plaques and tangles within the brain are taken into consideration as a number of the main functions of Alzheimer's disorder. every other feature is the lack of connections among nerve cells inside the brain. Neurons transmit messages between elements of the brain, and from the mind to muscle mass and organs in the body. Many different complex mind changes play an critical function in Alzheimer's.

This harm first of all seems within the hippocampus, the a part of the mind crucial in forming reminiscences. As neurons in mind die, extra elements of the mind are affected. The very last level of Alzheimer's, damage is big, and brain tissue has contracted notably.

The following test are used to detect Alzheimer disease

➤ **Blood test:-**



Diagram 2-Blood sample for Test

Blood is the ability supply of bookmark for Neurodegenerative alternate in mind due to the fact 500 ml of CSF is take in in to the blood each day. Moreover the common locating of blood mind barrier damage in Alzheimer's may also facilitated motion of protein from mind to blood. A blood check to come across the brain changes of early Alzheimer Disease has moved one steps in the direction of reality. The findings represent a key step closer to a blood take a look at to diagnose humans heading in the right direction to advanced extraordinary illnesses before symptoms get up.

The contemporary observe worried 15 adults of over age 50. Ten of the participant in the examine wherein cognitively everyday and each furnished at the least one blood pattern and underwent one puppy mind experiment.

The check of in advance version of which first watch pronounced to yr in the past use approach called as spectrometry to as it should be measure the quantity of two shape of amyloid beta in the blood.

Several recent studies has demonstrates that the blood biomarkers panels could be a splendid useful diagnostic equipment for identity of Alzheimer's patients.

➤ **Neuropsychometric check :-**

A previous retrospective cohort study inspecting descendants of profession of the PSEN1 E 280 A mutation pick out there predementia clinical level consistent with the Neurophysiological assessment

- 1.Asymptomatic Pre-MCI
- 2.Symptomatic Pre-MCI

The first identified scientific degree called Asymptomatic Pre-MCI became detected 11 to 15 yr before onset of dementia and characterised by means of Neurophysiological check scored to SD or more far from imply normal price score for non providers in at least one test on any cognitive domain and the absence of memory grievance and no effect on activities of day by day dwelling.

The second scientific tiers called Symptomatic Pre-MCI become time 5 to eleven yr before dementia and characterised via higher score in subjective mammary proceedings without or with minimum impermanent in complex instrumental feature.

The situation of circle of relatives Alzheimer sickness may be exceptional shape the sporadic Alzheimer Disease where different, age related factor make contributions to the priclinal and clinical outcome.

Therefore the end result from those examine might not be directly transfar able to the ones in spordic Alzheimer sickness.

➤ **Episodic memory check :-**

Episode 1 memory is the primary and maximum severally affected cognitive area in advert and in prodromal level along with amnesic MCI. Several degree may be used to asses episodic reminiscence consisting of the logical memory substest from the Wechsler memory scale.

The California verbal getting to know check, is now in second revision CVLT 2 and the loose and cured selective reminding test (FCSRT).


A number of the standardized Neurophysiological battery the FCSRT is also the maximum touchy and unique test for the analysis of prodromal Alzheimer sicknesses.

A massive look at analyzing members of circle of relatives With Dominantly Inherited Alzheimer sickness is referred to as DIAN examine.

The logical reminiscence check also used in potential research for sporadic Alzheimer disease and it has predicted Alzheimer sickness 10 year earlier than its medical prognosis.

the usage of episodic memory check which include Wechsler logical reminiscence test or the FCSRT allows early detection of subtle cognitive deficits in both familial Alzheimer sickness And sporadic Alzheimer disease favoring inclusions of this kind of test in a screening battery for detection of preclinical and early symptomatic Alzheimer disorder.

➤ Eye test:-



Digram:-3 Healthy person & Alzheimer person Difference

Ocular imaging might also offer a non invasive technique for the early detection and tracking of neurodegenerative sickness together with advert. The retina is an extension of brain this is extra handy for imaging. The response of student to light is largely driven with the aid of the cholinergic system, which is impaired by means of Alzheimer sickness. visible disturbance is frequently an early complaint in Alzheimer ailment patients and research have said decreased visible overall performance on exams of visual view, coloration vision, comparison sensitivity, backward protecting, visual attention, movement notion, shape from movement, visuospatial creation, and additionally visual reminiscence. Retinal morphology and a suppressed scholar mild reaction is formerly pronounced in Alzheimer sickness. In Alzheimer ailment adjustments to the vasculature and optic nerve head, retinal mobile loss and thinning of the retinal nerve fiber layer (RNFL) is mentioned in retinal morphology. A key look at located that Alzheimer Disease members had a particular pattern of RNFL thinning as narrower retinal blood column diameter and reduced retinal blood go with the flow. whilst this look at limited by means of its small length, different studies have supported and accelerated on the life of retinal vascular abnormalities in Alzheimer sickness. The retinal vascular modifications may be Summarized as vascular narrowing, reduced complexity of the branching sample, decreased optimality of the branching geometry, and much less tortuous venules. The pupil responding to a vibrant flash of light with slower pace and acceleration and a reduced amplitude of response, some retinal vascular reaction changes additionally discovered to be present in cognitively healthy individuals with excessive brain amyloid plaque burden, suggesting that eye checking out may also facilitate early detection of Alzheimer disorder. A latest have a look at investigated each the retina and scholar in familial Alzheimer sickness, demonstrating that cognitively healthy providers of the APPGlu693GIn mutation show off slower restoration from pupil flash reaction, with a hundred% separation between mutation vendors and non vendors. Amyloid plaques have also been mentioned in the postmortem retinas of Alzheimer disorder sufferers at early degrees. studies in animal Alzheimer disorder models have also determined Amyloid plaque burden in retina and mind correlate. The optic nerve without delay connects the mind to the returned of the eye.

Alzheimer's disease and dementia, which might be because of harm to mind cells, each appear to have effects on the retina of eye. a number of the retinal changes are determined the use of a short and common test known as optical coherence tomography (OCT).

a brand new have a look at has determined that human beings with Alzheimer's has fewer blood vessels and much less blood drift inside the retina of their eye.

The Alzheimer-related eye modifications have been detected through an eye fixed test that uses a scanning method known as optical coherence tomography angiography. it may take a look at blood vessels inside the retina which are a lot finer.the eye take a look at can be clean and new manner to stumble on early Alzheimer's sickness.

➤ **liver characteristic take a look at :-**

According to a latest examine unusual liver enzyme degrees detected by using usually used blood tests can be connected to Alzheimer's disease. The findings were posted on July 31 in JAMA community Open. Led through NIA supported scientific teams at Duke college and Indiana university, studies changed into primarily based on cause that strange modifications in liver enzymes are related to metabolic disorders like diabetes and coronary heart ailment which might be recognised danger elements for Alzheimer's. This observe set out to examine the connection among altered degrees of liver enzymes, indicating atypical liver feature, and diagnosis of Alzheimer's disorder.

1,581 peoples participated inside the NIA supported Alzheimer's ailment Neuroimaging Initiative. After evaluation covered outcomes are 407 people were healthy controls, 862 with memory concerns or moderate cognitive impairment, and 312 human beings identified with Alzheimer's disease. The researchers observed that peculiar stages of liver enzymes have been related to analysis of Alzheimer's and correlated with reminiscence and wondering in people with Alzheimer's disease. peculiar degrees are associated with extended tiers of amyloid within the brain, detected with the aid of positron emission tomography imaging, and reduced amyloid and expanded tiers of tau in cerebrospinal fluid. Accumulations of amyloid-beta and tau are the markers of Alzheimer's disorder. further, the researchers located that extraordinary liver enzyme stages were related to decreased glucose metabolism and extra shrinkage inside the parts of the brain.

This observe show that metabolic disturbances play a position in Alzheimer's disease procedures. however this study now not suggest whether or not bizarre degrees of liver enzymes reason the disorder or are a consequence.



Diagram 4 - Sample for Liver function test

➤ **MRI test :-**

MRI of the pinnacle :

Magnetic resonance imaging (MRI) makes use of a powerful magnetic subject, radio frequency pulses and a pc to provide particular pics of organs, gentle tissues, bone and simply all other inner frame organs. MRI can discover mind abnormalities related to moderate cognitive impairment and can be used to are expecting which sufferers with MCI may additionally probably develop Alzheimer's disease. In early tiers of Alzheimer's disorder, an MRI experiment of the mind can be ordinary. In later ranges of Alzheimer disorder, MRI may also display a lower inside the length of different regions of the brain.




Diagram 4 -Magnetic Resonance Imaging Test

❖ **Trompement of Alzheimer ailment:-**

At the moment there may be no remedy to be had for Alzheimer's sickness, symptomatic remedy can manipulate the disease and preserve the better exceptional of lifestyles. with the symptomatic remedy bodily workout and social pastime are also beneficial to hold typical appropriate health. higher changes in residing surroundings of affected person may be maintain comfort and dignity.

✓ **Non-Pharmacological tactics to treat Alzheimer's :**

The major method for the human beings of Alzheimer's is to catch up on cognitive potential that decline in affected person with the aid of supplying pleasant environment, assisting hand, sports, communication and programme. There are a few treatment domains that could compensate the cognitive characteristic in Alzheimer's.

Bodily environment remedy Plan:

physical surroundings promotes safety and reduces fear concerning cognition. The bodily environmental method demonstrated efficaciously in improving resident conduct and improving ranges of mind functioning. it's miles natural mapping method which it useful in presenting the information important for correct use of aspect by way of user. It promotes the feelings of safety and mastery, reduced degree of frustration.

Accepting Nature:

The most important cornerstone of non-pharmacological treatment is to understand and to assist the patient of Alzheimer's. there's need of strong communique between the humans with restricted word of recognition. by means of powerful conversation bring the patient of Alzheimer's to their feel of global. there is continually supporting hand to the patients of Alzheimer's in addition to to guide and provide the justification for everything to reduce the worry.

Motivation:

maintaining high quality feelings well as helping with activities of every day dwelling of Alzheimer's sufferers. assisting and motivating the patients that he or she will be able to do for themselves. Use particular ability and method that the individual with Alzheimer's participating of their personal care sports.

Therapeutic activities and programming:

people with dementia experience more psychiatric signs including tension, despair, fantasy and hallucinations. for that reason plan such therapeutic sports and programme which could change the poor emotions speedy and promote the emotions of fulfillment. The caregivers plan success orientated sports that concentrate on affected person cognitive strengths and keep away from the weak point generating skill.

Behaviours:

This form of treatment therapy focuses the behaviors of patients in preference to their feelings. There are number of things that may triggers the bad notion in patient for this reason such elements first perceive and eliminated so there might also reduce the hassle conduct. there are various approach stated to lessen the conduct disturbances in patient of Alzheimer's. consequently, analyze the behavior of patient for their negative feeling and notion and plan such intervention that could control the triggering elements.

Communicate modalities:

there's more than one communicate techniques can used such as use of familiar music, touching sensation, food odor use of non-verbal perception in Alzheimer's. there is impairment of receptive and expressive language abilities in Alzheimer's. consequently, the communicate with such patient isn't always done with phrases. communicate have to do with look, tone and hug that mirror feelings of protection and private care.

✓ **Pharmacological methods :**

It's miles important to take into account that there's no remedy available for complete treatment of Alzheimer's. there is numerous prescription drugs are currently authorised by using U.S. food and Drug management (FDA) for symptomatic relief in Alzheimer's. Symptomatic remedy of Alzheimer's may help the patients with consolation, dignity and independence for longer time frame. Such remedy can also help and encourages the caregivers. the principle method toward remedy of Alzheimer Diseases to improve the cholinergic transmission in the brain. these days, several medical trials shown that the anticholinesterase increases the extent of acetylcholine in brain through preventing its breakdown via cholinesterase enzyme. a few studies on Physostigmine indicate that there is temporary improvement in reminiscence following physostigmine in patients with advert. there is constrained use of physostigmine in Alzheimer's because of its short half-lifestyles and tendency to supply signs of systemic cholinergic excess at therapeutic doses.

Different anticholinesterases are tacrine, donepezil, rivastigmine and galantamine: reviews of all these marketers' shows to improve the memory performance of Alzheimer's. whilst there are stated a few aspect results of tacrine are stomach cramps, anorexia, nausea, vomiting, and diarrhoea at therapeutic dose level. there may be also said literature of elevations of serum transaminases due to those aspect outcomes, tacrine is not used broadly. as opposed to tacrine donepezil, rivastigmine and galantamine shows comparable development in memory and also has advantages to tacrine. relatively there are much less common and much less severe aspect outcomes than those found with tacrine; they consist of nausea, diarrhoea, vomiting and insomnia.

Capsules utilized in treatment of Alzheimer's sickness:-

1) Memantine

The class of Memantine drug is N-methyl D-aspartate (NMDA) antagonist drug. Memantine blocks the poisonous consequences related to extra glutamate and regulates glutamate activation. Memantine have some side outcomes because it produces headache, dizziness, constipation and confusion.

2) Galantamine

Galantamine is a cholinesterase inhibitor which prevents the hydrolysis of acetylcholine and stimulates nicotinic receptors to release extra acetylcholine inside the brain. Vomiting, nausea, diarrhoea, weight reduction are the side outcomes of Galantamine.

3) Rivastigmine

Rivastigmine is likewise protected within the category of cholinesterase inhibitor. Rivastigmine save you the breakdown of acetylcholine and butyrylcholine in the brain. With muscle weakness it produces equal facet outcomes as Galantamine.

4) Donepezil

Donepezil is a cholinesterase inhibitor which prevents the breakdown of acetylcholine in the mind. It produces nausea, vomiting and diarrhoea as a facet results.

❖ Remedy for mild to slight Alzheimer's:

tablets like cholinesterase inhibitors may additionally delay or prevent conduct symptoms specially cognitive related. the medicine consists of rivastigmine, donepezil, galantamine, tacrine are permitted Anticholinestrace retailers to apply in Alzheimer's. these pills prevent the breakdown of acetylcholine (neurotransmitter worried in memory and wondering). In Alzheimer's, there may be less amount of acetylcholine in brain therefore dealing with the hassle of cognitive decline. Cholinesterase inhibitors save you the hydrolysis of acetylcholine and thereby extended the extent and improve the cognitive overall performance.

❖ Remedy for moderate to extreme Alzheimer's:

Memantine, an N-methyl D-aspartate (NMDA) antagonist, is prescribed to use for moderate to excessive Alzheimer's disease. They produce delay in progression of some symptoms of Alzheimer's. automatically memantine act through regulating glutamate stage which is an important brain neurotransmitter. when there's excess quantity of glutamate consequences into brain cellular demise. NMDA antagonist paintings in another way in comparison to cholinesterase inhibitors. The drug permits preserving and performing positive every day features e.g. capability to apply of rest room independently for little longer than without medication.

healing objectives for disorder change in Alzheimer's:

The pathophysiological mechanism in Alzheimer's disease underlying the identification of molecular objectives for development of precise drugs. There are greater than 2 hundred pharmaceutical sellers are under clinical trial for treatment of Alzheimer's disease. those dealers categorized into anti-amyloid retailers and different pathophysiological targeted pills. Anti-amyloid tablets are designs to dam or inhibit the overproduction or aggregation B-amyloid protein. they're additionally design to favors clearance of B-amyloid protein from mind. while other category of medication are categorized consistent with their mechanism of movement like neurotransmitter and mobile signaling sellers, neuroprotective dealers, Tau primarily based cures, glial cell modulators. There are also present process stem mobile studies and gene remedy for treatment of Alzheimer's ailment. there may be position of immune reaction in Alzheimer's ailment. Immune reaction eliminates the excess soluble B-amyloid form from the circulate and thereby prevents the formation of B-amyloid plaque. Anti- B-amyloid immunotherapeutic agent designed to stimulate the soluble B-amyloid by-product immunogens to reduce the chance of secondary inflammatory responses or vasogenic oedema. these vaccines boom the immune reaction to better antibodies in opposition to B-amyloid monomers and oligomers.

❖ Prevantation and risks component of Alzheimer ailment:-

Prevention:-

There are a few sports that may hold mind healthy, we ought to practice them in each day life to save you from Alzheimer's.

those activities are like regular exercising, Social engagement, healthful weight-reduction plan, intellectual stimulation, pleasant sleep, pressure management, Vascular fitness and a few other activities.

studies display that the risk of Alzheimer's is not simplest restricted to antique age, in fact it is able to start within the mind lengthy before signs and symptoms are seen, probably in center age. It way there may be in no way too early to start taking approximately to attend to your brain fitness. The extra you follow wholesome way of life, the longer and stronger your mind will stay working and the much more likely you may be able to reduce your threat of growing Alzheimer's disease.

ordinary exercising

in keeping with the Alzheimer's research & Prevention basis, day by day physical exercising can lessen the risk of Alzheimer's ailment by way of up to 50 percent. exercising also can gradual down the improvement of Alzheimers in the ones who've already started out to expand related issues. exercise protects in opposition to Alzheimer's by means of stimulating the mind's capacity to keep old connections as well as make new nerve connection.

beginners have to be start with strolling and swimming. purpose at least a hundred and fifty minutes of the moderate depth workout every week, additionally exercising must involves a mixture of aerobic exercise and power education.

some weight and resistance education growth muscle tissue and allows to maintain brain fitness. humans's who're over sixty five, by adding 2-three energy periods in weekly recurring can be decline the hazard of Alzheimer's in half.

balance and coordination sporting activities must be blanketed. Head accidents can boom the risk of Alzheimer's ailment, safety measures need to be carried out all through paintings and exercise.

workout also gradually increase the self esteem and cope with the physical fitness of body with the stopping from Alzheimer's sickness.

Social engagement

Mankind is extraordinarily social creatures. Staying socially engaged may additionally even guard towards Alzheimer's disease in later existence, so make growing and increasing a sturdy community of pals.

humans's have to regularly connect face to face with someone different who cares approximately you and makes you experience heard. Many people become extra isolated as they become older, it's in no way too past due to fulfill others and increase new relationship.

to be socially lively there are some sports like

be a part of a membership or social group, Get to recognize your friends, Make a weekly date with friends, occasionally visit the park, museums, and different public places.

healthy weight-reduction plan

irritation and insulin resistance injure neurons and inhibit communication among brain cells in Alzheimer's ailment. Alzheimer's is occasionally defined as "diabetes of the mind". some studies suggests a robust link between metabolic issues and the sign processing systems between neurons. by means of a few desirable ingesting behavior, humans's can help to lessen irritation and to protect neurons signalling in brain.

greater weight is also threat aspect for Alzheimer's ailment. a main examine discovered that folks who had been overweight has twice possibilities to increase Alzheimer's. dropping the burden is manner to protecting your brain.

Sugary food can inflame your brain. enjoy a Mediterranean diet which means masses of vegetables, beans, entire grains, fish and olive oil and restricted processed meals.

Get the omega-three fat. DHA determined in these healthful fat can also help prevent Alzheimer's sickness and through decreasing beta-amyloid plaques.

devour fruit and veggies. As an awful lot extra fruits and vegetables, the extra better. eat up green leafy veggies, berries, and cruciferous greens which includes broccoli.

more often than not cook dinner at home. Drink sparsely or avoid consuming. heavy alcohol intake dramatically boost the threat of Alzheimer's sickness and accelerate growing older of brain.

intellectual stimulation

folks who retain getting to know new things and challenging their brains in the course of the existence are much less probable to develop Alzheimer's disorder. "use it or lose it."

sports which entails more than one responsibilities stimulates the mind.

have a look at a foreign languages, exercise a musical instruments. If greater the newness, complexity, and task, then extra the advantages.

play approach games, puzzles, and riddles. mind teasers and strategy games offer a mental exercise and build ability to form and hold cognitive institutions. Do a crossword puzzle, play board games, cards, or word and number games along with Scrabble and Sudoku.

exceptional sleep

there is link among poor sleep patterns and the development of Alzheimer's ailment. some studies have proven the significance of first-rate sleep for flushing out toxins inside the brain and poor sleep to better levels of beta-amyloid in the mind, a sticky protein that may further disrupt the sleep necessary for reminiscence formation. soo take good enough and deep sleep.

pressure control

Breathe! Quiet the pressure reaction with deep, stomach respiration. Restorative respiratory is powerful, simple, and unfastened!

agenda the every day rest activities. maintaining pressure underneath manipulate requires regular efforts. research relaxation techniques which includes meditation, modern muscle rest, or yoga can assist to unwind and reverse the dangerous results of stress.


regular meditation, prayer, and religious practice may additionally immunize towards the dangerous outcomes of pressure.

Make amusing a priority. maintain your sense of humor. The act of giggling enables your frame fight strain.

Vascular health

preserving the cardiovascular health it is able to be important in lowering your risk for unique types of dementia, including Alzheimer's disorder.

manage blood stress, hypertension or high blood stress is strongly associated with an expanded risk. high blood strain can harm the tiny blood vessels inside the components of the brain that is accountable for memory. Make wholesome weight loss program and healthy way of life changes. exercise, reducing your stress, and lowering salt, caffeine, and alcohol consumption can assist to decrease the blood stress. update processed food high in sodium with clean greens and fruit.



❖ Risk Factor:-

Age Related risk factor :

The distinction between everyday age associated reminiscence loss and in Alzheimer disease is addressed in graphs.

primary threat factors:

Advancing age of past 85 12 months increases danger through almost 50%. Direct member of the family with the ailment additionally increases the hazard of developing Alzheimers ailment.

Apolipoprotein E-e4 or APOE4 incorporates the most powerful threat of developing Alzheimer's ailment, this is a genetic mutation of APOE.

threat believed to boom if providers of the gene even have a annoying brain injury.

Cardiovascular risk elements:

mid-lifestyles obesity, mid-lifestyles high blood pressure, hyperlipidemia, diabetes mellitus will increase the danger of ad.

Genetic danger factors:

1. Predictive genetic checking out, with the counselling, can be supplied to the following at threat people with an apparent autosomal dominant inheritance whilst a circle of relatives precise mutation has been diagnosed.


a. First-diploma loved ones inclusive of kids and siblings of an affected man or woman with the mutation b.

First cousins of an affected man or woman if the not unusual ancestors died before the common age of onset of dementia inside the circle of relatives c. Nieces and nephews of an affected character whose discern died before the common age of onset of dementia in the family d. Minors aren't generally referred for predictive genetic trying out in Canada, but now and again such trying out can be taken into consideration on a case by case foundation by the relevant medical ethics committee.

Vascular chance factors:

1. decreasing the hazard of stroke, the prevalence of dementia can be decreased. The goal systolic blood strain should be ≤ 140 mm Hg.

2. there are numerous motives to deal with type 2 diabetes mellitus, hyperlipidemia and hyperhomocysteinemia, there may be insufficient evidence to recommend for treatment of these situations for the specific motive of reducing the danger of dementia.




Nongenetic chance elements Vascular hazard elements:

quantity of studies have proven that improved systolic blood pressure is related to an increased risk of each Alzheimer ailment and dementia, interestingly some studies have proven that a systolic blood strain underneath 140 mm Hg is likewise related to an increased threat. not with standing those and different reputedly contradictory findings, the consequences of the Systolic high blood pressure in Europe (SYST-EUR) look at found out a discounted threat of dementia among participants receiving antihypertensive treatment.

destiny instructions:

until few years ago, advert and dementia were no longer regarded as preventable. The transfer from fatalism to prevention on huge scale research in about two many years is a actual and crucial achievement, and the chance of delaying or preventing the onset of symptoms appears to be within attain. consequences from ongoing observational and intervention studies targeted mainly on Alzhimers ailment can make a contribution to identifying effective preventive techniques to unique danger of dementia like age, vascular/metabolic/lifestyle profiles, numerous biological markers and cognitive repute. There are obstacles to triumph over in future research. those consist of constantly improving and adapting fashions, criteria, definitions of disorder and the want for better studies strategies and infrastructure. The sturdy commitment of researchers to solve these troubles will accelerate the newly emerging or promising consequences into practical programs. The achievement of any campaign to save you Alzhimers disease would require sizable adjustments and improvements in the modern approach and philosophy to Alzheimer Diseasestudies. The relation between neuropathological modifications and cognitive impairment isn't always well understood until today. distinctly specific therapy for selected man or woman, for example, an autosomal dominant shape of Alzheimer Disease is a totally special shape of prevention than a population primarily based method in which the goal consists of a extensive variety of peoples with elevated threat of Alzhimers disease based totally on their lifestyle. In multifactorial situations, a small discount in multiple danger elements can considerably decrease typical threat. this is critical both on the character and populace tiers.

a few recent research show the predicted number of peoples with Alzhimers sickness in United kingdom primarily based at the data of 2010 and 2020 and the growth rate of peoples laid low with Alzhimers. In United country the range in 2010 is four.7 tens of millions, in 2020 it is 5.8 and it is projected to 13.8 by the 2050.



Projected number of people with Alzheimer's in US in million

Conclusion:-

Even though the pathogenesis of Alzheimer's ailment isn't always completely understood, primary preventions seems feasible as most factors concerned in Alzheimer's onset and development are modifiable or conceivable by using management. To the development of a success preventive strategies calls for a greater definite knowledge of risk and protecting factors for Alzheimer Diseases as well as observational research. Some latest studies suggest that the powerful method is to encourage the implementation of a couple of preventive measures during the life span, along with excessive instructional attainment in formative years and early adulthood, issues over maturity and active manipulation of vascular elements and protection of mentally, physically, and socially lively life at some point of center age and later in life. It's miles envisioned that half of Alzheimer's cases global are potentially on account of modifiable risk elements, and a 10% to 25% reduction in these factors should probably prevent three million Alzheimer's ailment instances global. The efficacy of preventive actions can also range by way of age. Accordingly, implementation of preventive measures at an appropriate time within the lifestyles route is very crucial for successful prevention.

In conclusion, prevention of Alzheimer's sickness is now shifting from the observational to interventional studies to confirm hypotheses and outline gear that may be carried out in the widespread population. Scientific and preclinical research will retain to offer new statistics on hazard and shielding factors and pathological mechanisms. The worldwide collaboration in studies teams will allow the sharing of reports and discussions on methodological factors of those research on Alzheimer's sickness. This will help in interpretation of outcomes, identification and solution of issues associated with intervention strategies, and refinement of preventative tactics since a remedy for Alzheimer's disease isn't always but to be had. Discovery of powerful preventive techniques is critical for a sustainable society in an ageing world. A few sicknesses like Alzheimer's, dementia, cardiovascular diseases, stroke, and diabetes mellitus are the essential public fitness problems and feature numerous equal chance factors, public health efforts selling a healthier way of life have the capability to decorate fitness popularity in older age.

References

1. webcite:-https://www.google.com/search?hl=en-IN&ie=UTF-uj8&source=android-browser&q=eye+test+for+Alzheimer+disease&client=Ms-android-xiaomi-rev1&gws_rd=ssl
2. Link's to the scienceb Yoon SP, Grewal DS, Thompsons AC et Retinal Microvascular and Neurodegenerative Changed in Alzheimer Disease and Mild Cognitive Impairment Compared with the Control ParticipantsuvOphthalmology Retina. This was published online March 12 2019 .
3. Journal Reference Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. High precision plasma amyloid- β 42/40 predicts current And future brain Amyloidosis. Neurology, 1 August, 2019 DOI : 10.1212/WNL.0000000000008081

4. Nho K, et al. Association of altered liver enzymes with Alzheimer disease diagnosis, cognition, Neuroimaging measures, and cerebrospinal fluid biomarkers. *JAMA Network Open*. 2019 ;2(7):e197978. doi: 10.1001/jamanetworkopen.2019.7978.
5. https://www.physio-pedia.com/Alzheimer%27_Disease#Xs1Os3NnO5Q ,
6. Ríona Mc Ardle, Rosie Morris, Aodhán Hickey, Silvia Del Din, Ivan Koychev, Roger N. Gunn, Jennifer Lawson, Giovanna Zamboni.
7. Basil Ridha, Barbara J. Sahakian, James B. Rowe, Alan Thomas, Henrik Zetterberg, Clare MacKay, Simon Lovestone, Lynn Rochesteron. Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. *Journal of Alzheimer's Disease*, 2018; 63 () 3233/JAD-17111 .
8. Dr. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 4584;34(7):939-44.
9. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The symptoms of mild cognitive impairment due to Alzheimer's disease recommendations from the National Institute on aging-alzheimer's Association work groups in diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement*. 2011;7(3):270-9. doi:10.1016/j.jalz.
10. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing review diagnostic process for Alzheimer's diseases: . *Lancet Neurol*, 2014;13(6):614-29. doi:10.1016/S1474-4422 (14)70090-0 .
11. Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*, 8, 595-608. doi:10.15252/emmm.201606210
12. Dorszewska, J., Predecki, M., Oczkowska, A., Dezor, M., & Kozubski, W. (2016). Molecular basis of familial and sporadic Alzheimer's disease. *Current Alzheimer Research*, 13, 952-63. doi:10.2174/1567205013666160531121003
13. Kametani, F., & Hasegawa, M. (2018). Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease. *Frontiers in Neuroscience*, 12, 25. doi:10.3389/fnins.2018.00025
14. Bhattacharya, S. K. (1999). Drugs acting on Central Nervous System. In S. D. Seth (Ed.), *Textbook of Pharmacology* (2nd ed., pp. 496-9). New Delhi: Elsevier.
15. Ellen, Y. S., & Kathryn, M. U. (1997). Donepezil: Anticholinesterase inhibitor for Alzheimer's disease. *American Journal of Health-System Pharmacy*, 54, 2805-10.
16. Marawar, A. P., Tilak, A. V., Mulkalwar, S. A., Sharma, S., Mathew, J., & Deshpande, T. A. (2014). Evaluation and Comparison of Effects of Donepezil and Aspirin on Working Memory in Rats. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 5(2), 1846.
17. Cachard-Chastel, M., Devers, S., Sicsic, S., Langlois, M., Lezoualc'h, F., & Gardier, A. M., et al. (2008). Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. *Behavioural Brain Research*, 187, 455-61. doi:10.1016/j.bbr.2007.09.030

18. Roy, A. (2018). Role of medicinal plants against Alzheimer's disease. *International Journal of Complementary and Alternative Medicine*, 11(4), 205-8.
19. Auddy, B., Ferreira, M., Blasina, F., Lafon, L., Arredondo, F., & Dajas, F., et al. (2003). Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. *Journal of Ethnopharmacology*, 84, 131-8. doi:10.1016/S0378-8741(02)00320-0
20. Eckert GP. Traditional used Plants against Cognitive Decline and Alzheimer Disease. *Frontiers in Pharmacology* [Internet]. 2010 Jan 1;1. Available from: <https://doi.org/10.3389/fphar.2010.00138>
21. Mahajan SM, Baviskar DT. Formulation development and evaluation of polyherbal suspension of some medicinal plants. *International Journal of Current Research and Review* [Internet]. 2021 Jan 1;13(12):99–106. Available from: <https://doi.org/10.31782/ijcrr.2021.131208>
22. Anand, R., Singh, S., & Singh, M. (2014). A Review on Phytoconstituents and Pharmacological Activities of *Tinospora Cordifolia* (Giloy). *Asian Journal of Pharmaceutical and Health Sciences*, 4(2), 721-729. [DOI: 10.13140/RG.2.1.3320.1761]
23. . Fatima U, Roy S, Ahmad S, Ali S, Elkady WM, Khan I, et al. Pharmacological attributes of *Bacopa monnieri* extract: Current updates and clinical manifestation. *Frontiers in Nutrition* [Internet]. 2022 Aug 18;9. Available from: <https://doi.org/10.3389/fnut.2022.972379>
24. Manap ASA, Vijayabalan S, Madhavan P, Chia YY, Arya A, Wong EH, et al. *Bacopa monnieri*, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies. *Drug Target Insights* [Internet]. 2019 Jul 31;13(1). Available from: <https://doi.org/10.33393/dti.2019.1417>
25. Jang J. Protective effect of resveratrol on β -amyloid-induced oxidative PC12 cell death. *Free Radical Biology & Medicine* [Internet]. 2003 Apr 15;34(8):1100–10. Available from: [https://doi.org/10.1016/s0891-5849\(03\)00062-5](https://doi.org/10.1016/s0891-5849(03)00062-5)
26. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Müller-Spahn F. Red Wine Ingredient Resveratrol Protects from β -Amyloid Neurotoxicity. *Gerontology* [Internet]. 2003 Jan 1;49(6):380–3. Available from: <https://doi.org/10.1159/000073766>
27. Li H, Wang X, Li P, Li Y, Wang H. Comparative study of antioxidant activity of grape (*Vitis vinifera*) seed powder assessed by different methods. *Yàowù Shípǐn Fēnxī* [Internet]. 2020 Jul 14;16(6). Available from: <https://doi.org/10.38212/2224-6614.2321>
28. Woo YJ, Joo YB, Jung YO, Ju JH, La Cho M, Oh HJ, et al. Grape seed proanthocyanidin extract ameliorates monosodium iodoacetate-induced osteoarthritis. *Experimental and Molecular Medicine/Experimental and Molecular Medicine* [Internet]. 2011 Jan 1;43(10):561. Available from: <https://doi.org/10.3858/emm.2011.43.10.062>
29. Woo YJ, Joo YB, Jung YO, Ju JH, La Cho M, Oh HJ, et al. Grape seed proanthocyanidin extract ameliorates monosodium iodoacetate-induced osteoarthritis. *Experimental and Molecular Medicine/Experimental and Molecular Medicine* [Internet]. 2011 Jan 1;43(10):561. Available from: <https://doi.org/10.3858/emm.2011.43.10.062>

30. Wang YJ, Thomas P, Zhong JH, Bi FF, Kosaraju S, Pollard A, et al. Consumption of grape seed extract prevents amyloid-B deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. *Neurotoxicity Research/Neurotoxicity Resarch* [Internet]. 2009 Jan 1;15(1):3–14. Available from: <https://doi.org/10.1007/s12640-009-9000-x>
31. Ahmad SF, Zoheir KMA, Abdel-Hamied HE, Ashour AE, Bakheet SA, Attia SM, et al. Grape seed proanthocyanidin extract has potent anti-arthritic effects on collagen-induced arthritis by modifying the T cell balance. *International Immunopharmacology* [Internet]. 2013 Sep 1;17(1):79–87. Available from: <https://doi.org/10.1016/j.intimp.2013.05.026>
32. Wang Y, Thomas P, Zhong J, Bi F, Kosaraju SL, Pollard A, et al. Consumption of grape seed extract prevents amyloid-B deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. *Neurotoxicity Research/Neurotoxicity Resarch* [Internet]. 2009 Jan 1;15(1):3–14. Available from: <https://doi.org/10.1007/s12640-009-9000-x>
33. Anand, R., Singh, S., & Singh, M. (2014). A Review on Phytoconstituents and Pharmacological Activities of *Tinospora Cordifolia* (Giloy). *Asian Journal of Pharmaceutical and Health Sciences*, 4(2), 721-729. [DOI: 10.13140/RG.2.1.3320.1761]
34. Hydroethanolic extract of *Sida rhombifolia* L. ameliorates scopolamine-induced cognitive dysfunction in rats Laxmi A. Pattanashetti1*, Basanagouda M. Patil1*, Harsha V. Hegde2 , Ranjit Kangle3 DOI: 10.7324/JAPS.2021.110516
35. Wang, R., Yan, X., Liu, J., Xu, H., Gou, T., Bai, T., & Guo, Y. (2006). Donepezil-induced neuroprotection in Alzheimer disease models. *CNS Neuroscience & Therapeutics*, 12(6), 675-682. [DOI: 10.1111/j.1755-5941.2006.00003.x]
36. :Review of the Pharmacological Effects of *Vitis vinifera* (Grape) and its Bioactive Constituents An Update Marjan Nassiri-Asl1 and Hossein Hosseinzadeh2
37. Jayaprakasha, G. K., Selvi, T., & Sakariah, K. K. (2003). Antibacterial and antioxidant activities of grape (*Vitis vinifera*) seed extracts. *Food Research International*, 36(2), 117-122. [DOI: 11.1016/S0963-9969(02)00151-X]
38. Iqbal K, Grundke-Iqbal A. Alzheimer's disease and cholinergic dysfunction. *Cold Spring Harb Perspect Med*. 2008;1(1):a006239. doi: 10.1002/cshperspect.a006239
39. Sugimoto H, Yamada T, Yokota T, Itoh Y, Saito K. Donepezil and other anti-Alzheimer's drugs: cholinesterase inhibitors or memory enhancers? *Curr Drug Targets*. 2000;1(2):151-9. doi: 10.2174/1389450003348713
40. Massoulié J, Sussman J, Bon S, Silman I. Structure and functions of acetylcholinesterase and butyrylcholinesterase. *Prog Brain Res*. 1993;98:139-46. doi:10.1016/S0079-6123(08)62250-0
41. Taylor P, Radic Z. The cholinesterases: from genes to proteins. *Annu Rev Pharmacol Toxicol*. 1994;34:281-320. doi:10.1146/annurev.pa.34.040194.001433

42. Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. *FEBS J.* 2008;275(4):625-32. doi:10.1111/j.1742-4658.2007.06243.x
43. Sperling LE, Steinert G, Boutter J, Landgraf D, Hescheler J, Pollet D, et al. Characterisation of cholinesterase expression during murine embryonic stem cell differentiation. *Chem Biol Interact.* 2008;175(1-3):156-60. doi:10.1016/j.cbi.2008.05.004
44. Paroanu LE, Layer PG. Acetylcholinesterase in cell adhesion, neurite growth and network formation. *FEBS J.* 2008;275(4):618-24. doi:10.1111/j.1742-4658.2007.06255.x
45. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. *Immunity.* 2009;31(6):965-73. doi:10.1016/j.immuni.2009.09.019
46. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer's disease. *J Neural Transm Suppl.* 2002;(62):181-7. doi:10.1007/978-3-7091-6139-5_18
47. Rossner S, Ueberham U, Schliebs R, Perez-Polo JR, Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. *Prog Neurobiol.* 1998;56(5):541-69. doi:10.1016/S0301-0082(98)00047-1
48. Robitzki A, Mack A, Hoppe U, Chatonnet A, Layer PG. Butyrylcholinesterase antisense transfection increases apoptosis in differentiating retinal reagggregates of the chick embryo. *J Neurochem.* 1998;71(4):413-20. doi:10.1046/j.1471-4159.1998.71041413.x
49. Zhang XJ, Yang L, Zhao Q, Caen JP, He HY, Jin QH, et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. *Cell Death Differ.* 2002;9(8):790-800. doi:10.1038/sj.cdd.4401031
50. Tracey KJ. Reflex control of immunity. *Nat Rev Immunol.* 2009;9:418-28. doi:10.1038/nri2566
51. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. *Nat Rev Neurosci.* 2005;6(1):48-56. doi:10.1038/nrn1588
52. Caulfield MP. Muscarinic receptors-characterization, coupling and function. *Pharmacol Ther.* 1993;58:319-79. doi:10.1016/0163-7258(93)90024-R
53. Levey AI, Edmonds SM, Koliatsos V, Wiley RG, Helman CJ. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. *J Neurosci.* 1995;15:4077-92. doi:10.1523/JNEUROSCI.15-05-04077.1995
54. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic receptor genes. *Science.* 1987;237(4818):527-32. doi:10.1126/science.3616608

55. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. *Neuron*. 1988;1(5):403-10. doi:10.1016/0896-6273(88)90198-1
56. Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. *Mol Pharmacol*. 1992;43(2):149-57. doi:10.1124/mol.43.2.149
57. Messer WS, Thomas GJ, Hoss W. Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task. *Brain Res*. 1987;407:37-45. doi:10.1016/0006-8993(87)91395-6
58. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. *Trends Pharmacol Sci*. 2009;30(3):148-55. doi:10.1016/j.tips.2008.12.001
59. Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1–M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. *Neurochem Res*. 2003;28(3/4):437-42. doi:10.1023/A:1022897932178
60. Messer WS, Thomas Jr. GJ, Hoss W. Selectivity of pirenzepine in the central nervous system. II. Differential effects of pirenzepine and scopolamine on performance of a representational memory task. *Brain Res*. 1987;407:37-45. doi:10.1016/0006-8993(87)91395-6
61. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. *J Neurosci*. 1991;11:3218-26. doi:10.1523/JNEUROSCI.11-11-03218.1991
62. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat Rev Drug Discov*. 2007;6(9):721-33. doi:10.1038/nrd2368
63. Hasselmo ME. The role of acetylcholine in learning and memory. *Curr Opin Neurobiol*. 2006;16(6):710-5. doi:10.1016/j.conb.2006.09.002
64. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. *Pharmacol Ther*. 2008;117(2):232-43. doi:10.1016/j.pharmthera.2007.10.003
65. Thimmapaya R, Kumar S, Salimath VP. Ayurvedic medicinal plants for Alzheimer's disease: a review. *J Altern Complement Med*. 2005;11(3):565-72. doi: 10.1089/acm.2005.11.565
66. Budson AE, Price BH. *Memory rehabilitation: a neurological and cognitive perspective*. New York: Oxford University Press; 2005.
67. Anderson MC. *Learning and memory: an integrated approach*. 5th ed. New York: Wiley; 2009.
68. Bartsch DM, Butler CR. *Memory disorders*. 2nd ed. Edinburgh: Churchill Livingstone; 2013.

69. Eysenck MW, Keane MT. *Cognitive psychology: a student handbook*. 5th ed. Hove: Psychology Press; 2005.
70. Gold JM. *Abnormal psychology*. 6th ed. Belmont, CA: Wadsworth Publishing Company; 2006.
71. Squire LR, Zola-Morgan JT. *The medial temporal lobe and memory consolidation*. Nat Rev Neurosci. 2008;8(5):347-57. doi: 10.1038/nrn2324
72. Blokland A. *Cholinergic modulation of memory function: pathophysiological aspects and therapeutic potential*. Eur J Pharmacol. 2006;545(1):3-10. doi: 10.1016/j.ejphar.2006.06.012
73. Renner U, Rupniak C, Morgan GJ, et al. *Regional distribution of [³H]scopolamine binding in the brain of the guinea pig*. Brain Res Bull. 2005;66(3):235-40. doi: 10.1016/j.brainresbull.2005.05.004
74. Schon K, Antonini A, Wehmann M, et al. *Scopolamine versus clozapine binding to human muscarinic acetylcholine receptors*. Neuropsychopharmacology. 2005;30(12):2107-11. doi: 10.1038/sj.npp.1300840
75. Bartus RT. *Cholinergic hypothesis of geriatric memory dysfunction*. Science. 1982;217(4558):408-14. doi: 10.1126/science.217.4558.408
76. Buccafusco JJ, Alloza C, Serrano A, et al. *Scopolamine-induced amnesia: a model for dementia?*. Behav Brain Res. 2008;187(2):244-52. doi: 10.1016/j.bbr.2007.12.005
77. Cunha C, Iadeia A, Rosa AR, et al. *Unmasking the cholinergic system in the pathophysiology of Alzheimer's disease and dementia*. Behav Pharmacol. 2008;19(5):403-10. doi: 10.1097/FCP.0b013e32830d09c2
78. Loiseau F, Bohr VM, Bénès FM, et al. *Scopolamine-induced amnesia in healthy young volunteers: a PET study of muscarinic receptor blockade on memory networks*. Brain. 2008;131(Pt 6):1533-46. doi: 10.1093/brain/awn067
79. Barak S, Weiner IB. *Combining cholinergic and glutamatergic approaches for the treatment of Alzheimer's disease*. Curr Neuropharmacol. 2009;7(2):135-44. doi: 10.2174/157015909788184808
80. Vaisman N, Pelled G. *Huperzine A for Alzheimer disease: a critical review of therapeutic evidence*. Curr Alzheimer Res. 2009;6(6):485-97. doi: 10.2174/156720509789032123
81. Spinks JD, Wasiak S. *Applications of animal models of learning and memory dysfunction in drug discovery*. Behav Brain Res. 2000;107(1-2):17-28. doi: 10.1016/S0149-7634(00)00132-4
82. Bejar MC, Lopez-Araque A, Granero L, et al. *Inhibitory effect of a standardized extract of Hypericum perforatum L. (Hypericum) on scopolamine-induced amnesia in rats*. J Psychopharmacol. 1999;13(2):144-50. doi: 10.1177/026988699901300207
83. Rubaj A, Siwek M, Różycka M, et al. *The effect of rivastigmine on memory and learning in a scopolamine model in rats*. Pharmacol Rep. 2003;55(3):379-84.
84. Jelic V, and Darreh-Shori T. Donepezil: A Review of Pharmacological Characteristics and Role in the Management of Alzheimer Disease. Clinical Medicine Insights: Therapeutics 2010; 2:771–788
85. Rai K, Gupta N, Dharamdasani L, Nair P, Bodhankar P. Bacopa Monnieri: A wonder drug changing fortune of people. Int J Appl Sci Biotechnol. 2017; 5(2):127. <http://doi.org/10.3126/ijasbt.v5i2.16952>
86. Aguiar S, and Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation research 2013; 16(4):313-326.

87. e-NIGHANTU (Collection of Ayurvedic Lexicons, National Institute of Indian Medical Heritage (NIIMH), Hyderabad/Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, Department of AYUSH, Ministry of Health and Family Welfare, Government of India. <http://niimh.nic.in/ebooks/eNighantu/> 02 – REVIEW OF LITERATURE Evaluation of Efficacy of Potentiated Brahmi Ghrita Using Animal Models 50

88. Acharya J.T., editor. Charaka Samhita of agnivesha (Ayurveda-Dipika commentary by Chakrapanidutta), Chaukhamba Surbharati Prakashan; Varanasi, India: 1992. p. 34. Sutrasthana, Shadvirechanashatashritiya, Chapter 4, Verse 18.

89. Acharya J.T., editor. Charaka Samhita of agnivesha (Ayurveda-Dipika commentary by Chakrapanidutta), Chaukhamba Surbharati Prakashan; Varanasi, India: 1992. p. 343. Sharirsthana, Jatisootriya, Chapter 8, Verse 20.

90. Shastri A. Bhaishajyaratnavali, second edition, Rasayan Prakaran, (73:182-196), Chaukhamba Prakashan; Varanasi, India: 2016. p. 1115.

91. Kishore K, Singh M. Effect of Bacopa monniera on animal models of learning and memory. *Int J Biomed Pharm Sci.* 2005;1(1):35-42.

92. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). *Indian J Pharmacol.* 1997;29(5):S359-S365.

93. Tripathi Y, Chaurasia S, Tripathi E, Upadhyay A, Dubey G. Bacopa monniera Linn. as an antioxidant: Mechanism of action. *Indian J Exp Biol.* 1996;34(6):523-526.

94. Ernst E. Herbal medicines for the treatment of psychiatric disorders: A systematic review. *Psychopharmacology (Berl)*. 2006;179(3):205-213.

95. Badmaev V. Clinical trials of Ayurvedic treatments for cognitive function. *J Altern Complement Med.* 1998;4(4):365-372.

96. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, Nathan PJ. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology (Berl)*. 2001;156(4):481-484.

97. Das A, Shanker G, Nath C, Pal R, Singh S, Singh HK. A comparative study in rodents of standardized Bacopa monniera extract and its two active constituents, bacoside A and B. *J Ethnopharmacol.* 2002;79(1):35-41.

98. Roodenrys S, Booth D, Bulzomi S, Phipps A, Micallef C, Smoker J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. *Neuropsychopharmacology.* 2002;27(2):279-281.

99. Raghav S, Singh H, Dalal PK, Srivastava JS, Asthana OP, Dhawan BN. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. *Indian J Psychiatry.* 2006;48(4):238-242.

100. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. *J Altern Complement Med.* 2008;14(6):707-713.

101. Hou CC, Lin SJ, Cheng JT, Hsu FL, Lee HS. Bacopaside III, bacopasaponin G, and bacopaside N: Three new saponins from Bacopa monniera. *Chem Pharm Bull (Tokyo)*. 2002;50(6):753-756.

102. Deepak M, Amit A, Venkataraman BV. Evaluation of the anti-inflammatory activity of standardized extracts of *Bacopa monniera* in experimental animals. **Phytother Res.** 2005;19(3):244-247.
103. Phrompittayarat W, Jetiyanon K, Wittaya-areekul S, Tanipongpipat S. Simultaneous determination of major saponins in *Bacopa monnieri* using HPLC. **J Pharm Biomed Anal.** 2007;43(2):959-965.
104. Basu N, Rastogi RP, Dhar ML. Chemical examination of *Bacopa monniera* Wettst: Part II—Bacoside B. **Indian J Chem.** 1967;5(3):84-86.
105. Singh HK, Singh N. Chemical examination of *Bacopa monniera* Wettst: Part III—Antioxidant properties. **J Nat Prod.** 1980;43(6):122-125.
106. Anbarasi K, Vani G, Devi CS. Protective effect of bacoside A on glutamate-induced oxidative stress in primary hippocampal culture. **Brain Res Bull.** 2006;68(6):391-395.
107. Nathan PJ, Lloyd J, Ricketts J, Wesnes K, Pincock C. The acute nootropic effects of *Bacopa monniera* in healthy elderly subjects. **J Psychopharmacol.** 2004;18(1):52-58.
108. Holcomb LA, Dhanasekaran M, Hitt AR. *Bacopa monniera* extract reduces amyloid levels in PSAPP mice. **J Alzheimers Dis.** 2006;9(3):243-251.
109. Dhanasekaran M, Tharakan B, Holcomb LA. Neuroprotective mechanisms of Ayurvedic antidementia botanical *Bacopa monniera*. **Phytother Res.** 2007;21(10):965-969.
110. Hota SK, Barhwal K, Singh SB. NR1 expression and NMDA receptor mediated calcium influx is down-regulated in hippocampus of *Bacopa monnieri* extract treated rats: Putative mechanism for its nootropic effect. **Neurochem Res.** 2009;34(6):1249-1257.
111. Bhattacharya SK, Ghosal S, Bhattacharya S. Antioxidant activity of *Bacopa monniera* in rat frontal cortex, striatum and hippocampus. **Phytother Res.** 2000;14(3):174-179.
112. Russo A, Izzo AA, Borrelli F. Free radical scavenging capacity and protective effect of *Bacopa monniera* L. on DNA damage. **Phytother Res.** 2003;17(8):870-875.
113. Chowdhuri DK, Parmar D, Kakkar P. Antistress effects of bacosides of *Bacopa monniera*: Modulation of Hsp70 expression, superoxide dismutase and cytochrome P450 activity in rat brain. **Phytother Res.** 2002;16(6):639-645.
114. Paulose CS, Chathu F, Khan I. *Bacopa monnieri* attenuates 5-HT_{2C} receptor function and gene expression in pilocarpine-induced epilepsy in rats. **J Neurosci Res.** 2007;85(2):421-429.
115. Limpeanchob N, Jaipan S, Rattanakaruna S. Neuroprotective effect of *Bacopa monnieri* on beta-amyloid-induced cell death in primary cortical cultures. **J Ethnopharmacol.** 2008;120(1):112-117.
116. Tripathi Y, Chaurasia S, Tripathi E, Upadhyay A, Dubey G. *Bacopa monniera* Linn. as an antioxidant: Mechanism of action. **Indian J Exp Biol.** 1996;34(6):523-526.
117. Baydar, NG, Ozkan, G & Sağdıç, O (2004) Total phenolic contents and antibacterial activities of grape (*Vitis vinifera* L.) extracts. *Food Control*, 15(3), 335-339.
118. Bentivegna, SS & Whitney, KM (2002) Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. *Food and Chemical Toxicology*, 40(12), 1731-1743. doi: [10.1016/S0278-6915\(02\)00091-X](https://doi.org/10.1016/S0278-6915(02)00091-X)
119. Wayne, RL & Mahinda, YA (2008) Cardioprotective actions of grape polyphenols. *Nutrition Research*, 28(11), 729-737. doi: [10.1016/j.nutres.2008.09.001](https://doi.org/10.1016/j.nutres.2008.09.001)

120. Georgiev, V, Ananga, A & Tsoleva, V (2014) Recent Advances and uses of Grape Flavonoids as Nutraceuticals. *Nutrafoods*, 6(4), 391-415.

121. Nadkarni, KM & Nadkarni, AK (2005) *Indian Materia Medica*. Popular Prakashan.

122. Arya Vaidya Sala (2003) *Indian Medicinal Plants*. Orient Longman Private Limited.

123. El-Hawary, S, El-Fouly, K, El Gohary, HM, Meselhy, KM, Slem, A & Talaat, Z (2010) Phytochemical and Biological Investigation of *Vitis vinifera* L. (Flame cultivar), Family Vitaceae Cultivated in Egypt. *Natural Science*, 10(10), 48-59.

124. Monagas, M, Garrido, I, Bartolome, B & Cordoves, CG (2006) Chemical characterization of commercial dietary ingredients from *Vitis vinifera* L. *Analytica Chimica Acta*, 563(1-2), 401-410. doi: [10.1016/j.aca.2006.01.024](https://doi.org/10.1016/j.aca.2006.01.024)

125. Youssef, D & El-Adawi, H (2006) Study on grape seeds Extraction and optimization: An Approach. *Journal of Applied Sciences*, 6(18), 2944-2947.

126. Yamakoshi, J, Saito, M, Kataoka, S & Kikuchi, M (2002) Safety evaluation of proanthocyanidin-rich extract from grape seeds. *Food and Chemical Toxicology*, 40(5), 599-607. doi: [10.1016/S0278-6915\(01\)00099-7](https://doi.org/10.1016/S0278-6915(01)00099-7)

127. Pekic, B, Kovac, V, Alonso, E & Revilla, E (1998) Study of the extraction of proanthocyanidins from grape seeds. *Food Chemistry*, 61(2), 201-206. doi: [10.1006/fchi.1997.0242](https://doi.org/10.1006/fchi.1997.0242)

128. Zdunczyk, Z, Frejnagel, S, Wroblewska, M, Juskiewiewicz, J, Oszmianski, J, Estrella, I, et al. (2002) Biological activity of polyphenol extracts from different plant sources. *Food Research International*, 35(2), 183-186. doi: [10.1016/S09](https://doi.org/10.1016/S09)

129. Stevenson, DE (2012) Bioactive compounds in phytomedicine. IntechOpen. [Book Chapter]

130. Soong, YY & Barlow, PJ (2004) Antioxidant activity and phenolic content of selected fruit seeds. *Food Chemistry*, 88(3), 411-417. doi: [10.1016/j.foodchem.2003.11.002](https://doi.org/10.1016/j.foodchem.2003.11.002)

131. Iacopini, P, Baldi, M, Storchi, P & Sebastiani, L (2008) Catechin, epicatechin, Quercetin, rutin and resveratrol in red grape: Content, in vitro antioxidant activity and interactions. *Journal of Food Composition and Analysis*, 21(6), 589-598. doi: [10.1016/j.jfca.2008.03.008](https://doi.org/10.1016/j.jfca.2008.03.008)

132. Bagchi, D, Bagchi, M, Stohs, SJ, Das, DK, Rav, SD, et al. (2008) Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. *Toxicology*, 148(1-3), 187-197. doi: [10.1016/j.tox.2008.02.001](https://doi.org/10.1016/j.tox.2008.02.001)

133. Akhlaghi, M & Bandy, B (2009) Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. *Journal of Molecular and Cellular Cardiology*, 46(3), 309-317. doi: [10.1016/j.yjmcc.2008.11.004](https://doi.org/10.1016/j.yjmcc.2008.11.004)

134. Feng, Y, Liu, YM, Fratkins, JD & LeBlanc, MH (2005) Grape seed extract suppresses lipid peroxidation and reduces hypoxic ischemic brain injury in neonatal rats. *Brain Research Bulletin*, 66(2), 120-127. doi: [10.1016/j.brainresbull.2005.04.008](https://doi.org/10.1016/j.brainresbull.2005.04.008)

135. Kim, H, Deshane, J, Barnes, S & Meleth, S (2006) Proteomics analysis of the actions of grape seed extract in rat brain; Technological and biological implications for the study of the actions of psychoactive compounds. *Life Sciences*, 78(20), 2060-2065. doi: [10.1016/j.lfs.2005.11.032](https://doi.org/10.1016/j.lfs.2005.11.032)
136. Sarkaki, A, Rafieirad, M, Seyed, EH, Farbood, Y, Motamedi, F, et al. (2013) Improvement in Memory and Brain Long-term Potentiation Deficits Due to Permanent Hypoperfusion/Ischemia by Grape Seed Extract in Rats. *Iranian Journal of Basic Medical Sciences*, 16(8), 1004-1010.
137. Pari, L & Suresh, A (2008) Effect of Grape (*Vitis vinifera* L.) leaf extract on alcohol induced oxidative stress in rats. *Food and Chemical Toxicology*, 46(7), 1627-1634. doi: [10.1016/j.fct.2008.02.012](https://doi.org/10.1016/j.fct.2008.02.012)
138. Balu, M, Sangeetha, P, HariPriya, D & Panneerselvam, C (2005) Rejuvenation of antioxidant system in central nervous system of aged rats by grape seed extract. *Neuroscience Letters*, 383(3), 295-300. doi: [10.1016/j.neulet.2005.04.008](https://doi.org/10.1016/j.neulet.2005.04.008)
139. Balu, M, Sangeetha, P, Murali, G & Panneerselvam, C (2005) Age-related oxidative protein damages in central nervous system of rats: modulatory role of grape seed extract. *International Journal of Developmental Neuroscience*, 23(5), 501-507. doi: [10.1016/j.ijdevneu.2005.02.002](https://doi.org/10.1016/j.ijdevneu.2005.02.002)
140. Balu, M, Sangeetha, P, Murali, G & Panneerselvam, C (2006) Modulatory role of grape seed extract on age-related oxidative DNA damage in central nervous system of rats. *Brain Research Bulletin*, 68(6), 469-473. doi: [10.1016/j.brainresbull.2005.12.003](https://doi.org/10.1016/j.brainresbull.2005.12.003)
141. Baydar, NG, Ozkan, G & Yasar, S (2007) Evaluation of the antiradical and antioxidant potential of grape extracts. *Food Control*, 18(11), 1131-1136. doi: [10.1016/j.foodcont.2006.10.020](https://doi.org/10.1016/j.foodcont.2006.10.020)
142. Seruga, M, Novak, I & Jakobek, L (2011) Determination of polyphenols content and antioxidant activity of some red wines by differential pulse voltammetry, HPLC and spectrophotometric methods. *Food Chemistry*, 124(4), 1208-1216. doi: [10.1016/j.foodchem.2010.08.032](https://doi.org/10.1016/j.foodchem.2010.08.032)
143. Katalinic, V, Mozina, SS, Skroza, D, Generalic, I, Abramovic, H, et al. (2010) Polyphenolic profile, antioxidant properties and antimicrobial activity of grape skin extracts of 14 *Vitis vinifera* varieties grown in Dalmatia (Croatia). *Food Chemistry*, 119(3), 715-723. doi: [10.1016/j.foodchem.2009.09.032](https://doi.org/10.1016/j.foodchem.2009.09.032)
144. Erguder, IB, Cetin, R, Devrim, E, Kilicoglu, B, Aveli, A, Durak, I, et al. (2005) Effects of cyclosporine on oxidant/antioxidant status in rat ovary tissues: Protective role of black grape extract. *International Immunopharmacology*, 5(7-8), 1311-1315. doi: [10.1016/j.intimp.2005.02.008](https://doi.org/10.1016/j.intimp.2005.02.008)
145. Montagut, G, Baiges, I, Valls, J, Terra, X, Bas, JMD, et al. (2009) A timer plus a dimer[1]gallate reproduce the bioactivity described for an extract of grape
146. Xu, J, Wu, J, Sun, Y, Bao, L & Chen, S (2007) Effect of grape seed proanthocyanidin extract on learning and memory in ovariectomized rats. *European Journal of Pharmacology*, 579(1-3), 424-431. doi: [10.1016/j.ejphar.2007.09.047](https://doi.org/10.1016/j.ejphar.2007.09.047)
147. Wei, A, Zhao, Y & Zhang, Z (2010) Neuroprotective effects of grape seed proanthocyanidin extract on focal cerebral ischemia-reperfusion injury in rats. *Neurological Research*, 32(8), 833-839. doi: [10.1177/1070550X10377022](https://doi.org/10.1177/1070550X10377022)

148. Shukitt-Hale, B, McEwen, BS & Joseph, JA (2009) Grape seed proanthocyanidin extract attenuates age-related cognitive decline in APP25 transgenic mice. *Neuropsychopharmacology*, 34(2), 537-549. doi: [10.1038/npp.2008.51](https://doi.org/10.1038/npp.2008.51)
149. O.P. Rout, R. Acharya, R. Gupta, S.R. Inchulkar, K.S. Karbhal, R. Sahoo, Management of psychosomatic disorders through ayurvedic drugs-A Critical Review, *World J. Pharmac. Pharmaceuti. Sci.* 2 (2013) 6507-6537.
150. S. Satyanarayana, N. Srinivas, K. Rajabhanu, K. Sushruta, M.B. Krishna, Adaptogenic and nootropic activities of aqueous extract of *Vitis vinifera* (grape seed): An experimental study in rat model, *BMC. Complemen. Alternat. Med.* 5 (2005) 1-8
151. H.Y. Jin, Y.S. Cha, H.S. Baek, T.S. Park, Neuroprotective effects of *Vitis vinifera* extracts on prediabetic mice induced by a high-fat diet, *Korean J. Intern. Med.* 28 (2013) 579-586.
152. D. Bagchi, A. Garg, R.L. Krohn, M. Bagchi, D.J. Bagchi, et.al. Protective effects of grape seed Proanthocyanidins and selected Antioxidants against TPA-Induced Hepatic and Brain Lipid Peroxidation and DNA Fragmentation, and Peritoneal Macrophage Activation in mice, *Gen. pharmac.* 30 (1998) 771-776.
153. Anamarija I. Mandic, Sonja M. Dilas, Gordana S. Četković, Jasna M. Canadanovic-Brunet & Vesna T. Tumbas (2008) Polyphenolic Composition and Antioxidant Activities of Grape Seed Extract, *International journal of Food Properties*, 11:4, 713-726, DOI: [10.1080/10942910701584260](https://doi.org/10.1080/10942910701584260)
154. Squire LR, Wixted JT. *The medial temporal lobe and memory consolidation*. *Nat Rev Neurosci.* 2008;8(5):347-57. doi: [10.1038/nrn2324](https://doi.org/10.1038/nrn2324)
155. Mahajan, S. M., & Baviskar, D. T. (2021). Formulation development and evaluation of polyherbal suspension of some medicinal plants. *International Journal of Current Research and Review*, 13(12), 100-106. [DOI: [10.31782/IJCRR.2021.131208](https://doi.org/10.31782/IJCRR.2021.131208)]
156. Jain NK, Sharma SN. *Textbook of Professional Pharmacy*. 3rd ed. New Delhi: Vallabh Prakashan; 1994. p. 228.
157. McClure N. *Stability studies: an overview of ICH guidelines for drug products*. Matrix Pharmaceutical Inc.; 1997.
158. Mahato RI. *Pharmaceutical dosage forms and drug delivery*. Boca Raton: CRC Press, Taylor & Francis Group; 2007. p. 123-133.
159. *Test No. 423: Acute Oral toxicity – Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4*, OECD Publishing: Paris, 2002.
160. Malik MK, Bhatt P, Singh J, Kaushik RD, Sharma G, Kumar V. Preclinical Safety Assessment of Chemically Cross-Linked Modified Mandua Starch: Acute and Sub-Acute Oral Toxicity Studies in Swiss Albino Mice. *ACS Omega.* 2022 Oct 11;7(40):35506-35514. doi: [10.1021/acsomega.2c01309](https://doi.org/10.1021/acsomega.2c01309). PMID: [36249409](https://pubmed.ncbi.nlm.nih.gov/36249409/). PMID: 36249409.

161. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I. Effects of cannabinoid and glutamate receptor antagonists and their interactions on learning and memory in male rats. *Pharmacology, Biochemistry and Behavior* [Internet]. 2015 Apr 1;131:87–90. Available from: <https://doi.org/10.1016/j.pbb.2015.02.005>
162. Komaki A, Karimi SA, Salehi I, Sarihi A, Shahidi S, Zarei M. The treatment combination of vitamins E and C and astaxanthin prevents high-fat diet induced memory deficits in rats. *Pharmacology, Biochemistry and Behavior* [Internet]. 2015 Apr 1;131:98–103. Available from: <https://doi.org/10.1016/j.pbb.2015.02.008>
163. Lashgari R, Motamedi F, Asl S, Shahidi S, Komaki A. Behavioral and electrophysiological studies of chronic oral administration of L-type calcium channel blocker verapamil on learning and memory in rats. *Behavioural Brain Research* [Internet]. 2006 Aug 10;171(2):324–8. Available from: <https://doi.org/10.1016/j.bbr.2006.04.013>
164. Barzegar S, Komaki A, Shahidi S, Sarihi A, Mirazi N, Salehi I. Effects of cannabinoid and glutamate receptor antagonists and their interactions on learning and memory in male rats. *Pharmacology, Biochemistry and Behavior* [Internet]. 2015 Apr 1;131:87–90. Available from: <https://doi.org/10.1016/j.pbb.2015.02.005>
165. Shahidi S, Komaki A, Mahmoodi M, Lashgari R. The role of GABAergic transmission in the dentate gyrus on acquisition, consolidation and retrieval of an inhibitory avoidance learning and memory task in the rat. *Brain Research* [Internet]. 2008 Apr 1;1204:87–93. Available from: <https://doi.org/10.1016/j.brainres.2008.02.008>
166. Saikia B, Barua C, Sarma J, Haloi P, Tamuli S, Kalita D, et al. Zanthoxylum alatum ameliorates scopolamine-induced amnesia in rats: Behavioral, biochemical, and molecular evidence. *Indian Journal of Pharmacology/the Indian Journal of Pharmacology* [Internet]. 2018 Jan 1;50(1):30. Available from: https://doi.org/10.4103/ijp.ijp_417_17
167. Y S, T VK. EVALUATION OF ANTI-ALZHEIMER ACTIVITY OF ETHANOLIC AND METHANOLIC EXTRACTS OF POLYGONUM GLABRUM AGAINST ALUMINUM CHLORIDE-INDUCED ALZHEIMER'S IN EXPERIMENTAL RATS. *Asian Journal of Pharmaceutical and Clinical Research* [Internet]. 2021 Jan 5;118–25. Available from: <https://doi.org/10.22159/ajpcr.2021.v14i1.39934>
168. Kramer GF, Norman HA, Krizek DT, Mirecki RM. Influence of UV-B radiation on polyamines, lipid peroxidation and membrane lipids in cucumber. *Biochim Biophys Acta*. 1991 Jun 28;1056(1):56-64. doi: 10.1016/0304-4165(79)90289-7.
169. Slater TF. Overview of methods used for detecting lipid peroxidation. *Methods Enzymol*. 1984;105:283-293. doi: 10.1016/S0076-6879(84)05036-9.
170. Rahimzadegan M, Soodi M. Comparison of Memory Impairment and Oxidative Stress Following Single or Repeated Doses Administration of Scopolamine in Rat Hippocampus. *Basic Clin Neurosci*. 2018;9(1):5-14. doi: 10.29252/NIRP.BCN.9.1.5. PMID: 29942435. PMCID: PMC6015638.
171. Nigam A, Kulshreshtha M, Panjwani D. Pharmacological evaluation of Hibiscus abelmoschus against scopolamine-induced amnesia and cognitive impairment in mice. *Adv Hum Biol*. 2019;9:116-23. doi: 10.4103/AIHB.AIHB_3_19.
172. Kshirsagar SN, Sakarkar DM, Deshpande SS. Learning and memory enhancing activity of ethanolic extract of dried seed kernels of Caesalpinia crista Lin. in albino mice. *Pharm Glob Int J Compr Pharm*. 2012;3(9):1-5. Available online: 5 September 2012.

173. Khurana N, Sharma N, Patil S, Gajbhiye A. Ameliorative effect of *Sida cordifolia* L. against scopolamine-induced cognitive deficit in mice model.
174. Sridhar GR. Acetylcholinesterase inhibitors (Galantamine, Rivastigmine, and Donepezil). In: Riederer P, Laux G, Nagatsu T, Le W, Riederer C, editors. *NeuroPsychopharmacotherapy*. Cham: Springer; 2021. doi: 10.1007/978-3-319-56015-1_418-1.
175. Kosaraju J, Madhunapantula SV, Chinni S, Khatwal RB, Dubala A, Nataraj SKM, Basavan D. Dipeptidyl peptidase-4 inhibition by *Pterocarpus marsupium* and *Eugenia jambolana* ameliorates streptozotocin-induced Alzheimer's disease. *Behav Brain Res*. 2014 Jun 15;267:49-58. doi: 10.1016/j.bbr.2014.03.026.
176. Schacter GB, Yang CR, Innis NK, Mogenson GJ. The role of the hippocampal-nucleus accumbens pathway in radial-arm maze performance. *Brain Res*. 1989;494(2):339-349. doi: 10.1016/0006-8993(89)90602-1.
177. Toledano A, Alvarez MI. Lesions and dysfunctions of the nucleus basalis as Alzheimer's disease models: general and critical overview and analysis of the long-term changes in several excitotoxic models. *Curr Alzheimer Res*. 2004;1(3):189-214. doi: 10.2174/1567205043332117.
178. Hyde LA, Hoplight BJ, Denenberg VH. Water version of the radial-arm maze: learning in three inbred strains of mice. *Brain Res*. 1998 Jan 19;785(2):236-244. doi: 10.1016/S0006-8993(97)01417-0.
179. Olton DS. The radial arm maze as a tool in behavioral pharmacology. *Physiol Behav*. 1987;40(6):793-797. doi: 10.1016/0031-9384(87)90286-1.
180. Hiramatsu M, Inoue K. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. *Psychopharmacology (Berl)*. 2000 Jun;150(3):311-316. doi: 10.1007/s002130000390.
181. Narayanan G, Prabhu K, Chaudhuri A, Rao MRK, Selvi VSK, Balaji TK, Kanagasabai V, Dinakar S. Neuro-protective effect of Ayurveda formulation, Saraswatharishtam, on scopolamine induced memory impairment in animal model. *Pharmacogn J*. 2020;12(2):357-364. doi: 10.5530/pj.2020.12.72.
182. Singh SK, Srivastav S, Yadav AK, Srikrishna S, Singh RK, Sridhar C, et al. *Asparagus adscendens* root extract enhances cognition and protects against scopolamine-induced amnesia: An in-silico and in-vivo study. *Chem Biol Interact*. 2016 Dec 5;260:8-17. doi: 10.1016/j.cbi.2016.10.007.
183. Nigam A, Kulshreshtha M, Panjwani D. Pharmacological evaluation of *Hibiscus abelmoschus* against scopolamine-induced amnesia and cognitive impairment in mice. *Adv Hum Biol*. 2019;9:116-123. doi: 10.4103/AIHB.AIHB_3_19.
184. (2021). Hydroethanolic extract of *Sida rhombifolia* L. ameliorates scopolamine-induced cognitive dysfunction in rats. *J Appl Pharm Sci* **11(05):**118-126. doi: 10.7324/JAPS.2021.110516